The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.

Bone morphogenetic proteins (BMPs) signal through the BMP type I and type II receptors to regulate cellular processes, including embryonic development. The type I BMP receptors activin-like kinase (ALK)3 and ALK6 share a high degree of homology, yet possess distinct signaling roles. Here, we report that although the transforming growth factor (TGF)-beta type III receptor (TbetaRIII) enhanced both ALK3 and ALK6 signaling, TbetaRIII more potently enhanced ALK6-mediated stimulation of the BMP-responsive promoters XVent2 and 3GC2, and up-regulation of the early response gene Smad6. In contrast, TbetaRIII specifically enhanced ALK3-mediated up-regulation of the early response gene ID-1. TbetaRIII associated with ALK3 primarily through their extracellular domains, whereas its interaction with ALK6 required both the extracellular and cytoplasmic domains. TbetaRIII, along with its interacting scaffolding protein beta-arrestin2, induced the internalization of ALK6. In contrast, TbetaRIII colocalized with and resulted in the cell surface retention of ALK3, independently of beta-arrestin2. Although complex formation between TbetaRIII, ALK6, and beta-arrestin2 and TbetaRIII/ALK6 internalization resulted in maximal BMP signaling, the TbetaRIII mutant unable to interact with beta-arrestin2, TbetaRIII-T841A, was unable to do so. These studies support a novel role for TbetaRIII in mediating differential ALK3 and ALK6 subcellular trafficking resulting in distinct signaling downstream of ALK3 and ALK6.

[1]  G. Blobe,et al.  The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42 , 2009, Proceedings of the National Academy of Sciences.

[2]  R. Mansel,et al.  Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. , 2009, Cancer genomics & proteomics.

[3]  H. You,et al.  Endocytosis of the Type III Transforming Growth Factor-β (TGF-β) Receptor through the Clathrin-independent/Lipid Raft Pathway Regulates TGF-β Signaling and Receptor Down-regulation* , 2008, Journal of Biological Chemistry.

[4]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[5]  G. Blobe,et al.  Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-β Type III Receptor* , 2008, Journal of Biological Chemistry.

[6]  G. Blobe,et al.  TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. , 2008, Carcinogenesis.

[7]  G. Blobe,et al.  Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. , 2008, Carcinogenesis.

[8]  H. You,et al.  The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. , 2007, Carcinogenesis.

[9]  H. Beppu,et al.  Repulsive Guidance Molecule RGMa Alters Utilization of Bone Morphogenetic Protein (BMP) Type II Receptors by BMP2 and BMP4* , 2007, Journal of Biological Chemistry.

[10]  S. Murphy,et al.  Loss of betaglycan expression in ovarian cancer: role in motility and invasion. , 2007, Cancer research.

[11]  G. Blobe,et al.  The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. , 2007, Cancer research.

[12]  B. Moeller,et al.  The type III TGF-β receptor suppresses breast cancer progression , 2007 .

[13]  Kellye C. Kirkbride.  Elucidating the role of the transforming growth factor-beta type III receptor in bone morphogenetic protein signaling , 2007 .

[14]  Y. Henis,et al.  Different Routes of Bone Morphogenic Protein (BMP) Receptor Endocytosis Influence BMP Signaling , 2006, Molecular and Cellular Biology.

[15]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[16]  R. Akhurst,et al.  Mutations of TGFbeta signaling molecules in human disease. , 2006, Annals of medicine.

[17]  D. Ovchinnikov,et al.  Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Knaus,et al.  Dynamics and interaction of caveolin-1 isoforms with BMP-receptors , 2005, Journal of Cell Science.

[19]  Xiao-Fan Wang,et al.  ß-Arrestin 2 Mediates Endocytosis of Type III TGF-ß Receptor and Down-Regulation of Its Signaling , 2003, Science.

[20]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[21]  R. Weinberg,et al.  Heart and Liver Defects and Reduced Transforming Growth Factor β2 Sensitivity in Transforming Growth Factor β Type III Receptor-Deficient Embryos , 2003, Molecular and Cellular Biology.

[22]  Jeffrey L. Wrana,et al.  Distinct endocytic pathways regulate TGF-β receptor signalling and turnover , 2003, Nature Cell Biology.

[23]  Guang-Quan Zhao,et al.  Consequences of knocking out BMP signaling in the mouse , 2003, Genesis.

[24]  F. López‐Casillas,et al.  Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. , 2002, Cancer research.

[25]  Jian Luo,et al.  Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells , 2002, Oncogene.

[26]  K. Fu,et al.  Signalling via type IA and type IB bone morphogenetic protein receptors (BMPR) regulates intramembranous bone formation, chondrogenesis and feather formation in the chicken embryo. , 2002, The International journal of developmental biology.

[27]  R. Behringer,et al.  Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Lodish,et al.  A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. , 2001, The Journal of biological chemistry.

[29]  Jean Gruenberg,et al.  The endocytic pathway: a mosaic of domains , 2001, Nature Reviews Molecular Cell Biology.

[30]  J. Massagué,et al.  TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders , 2000, Cell.

[31]  Y G Chen,et al.  Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Müllerian hormone and its type II receptor. , 2000, The Journal of biological chemistry.

[32]  L. Gilboa,et al.  Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. , 2000, Molecular biology of the cell.

[33]  K. Miyazono,et al.  Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. , 1999, Journal of cell science.

[34]  V. Rosen,et al.  Differential Roles for Bone Morphogenetic Protein (BMP) Receptor Type IB and IA in Differentiation and Specification of Mesenchymal Precursor Cells to Osteoblast and Adipocyte Lineages , 1998, The Journal of cell biology.

[35]  K. Miyazono,et al.  Signal transduction by bone morphogenetic proteins. , 1998, Cytokine & growth factor reviews.

[36]  T. Yoneda,et al.  Smad5 and DPC4 Are Key Molecules in Mediating BMP-2-induced Osteoblastic Differentiation of the Pluripotent Mesenchymal Precursor Cell Line C2C12* , 1998, The Journal of Biological Chemistry.

[37]  J. Massagué,et al.  The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. , 1997, Genes & development.

[38]  Teruhiko Yoshida,et al.  Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs , 1997, Oncogene.

[39]  K. Miyazono,et al.  Identification of Type I and Type II Serine/Threonine Kinase Receptors for Growth/Differentiation Factor-5* , 1996, The Journal of Biological Chemistry.

[40]  D. L. Griffith,et al.  Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Behringer,et al.  Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. , 1995, Genes & development.

[42]  K. Miyazono,et al.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Massagué,et al.  Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs , 1995, Molecular and cellular biology.

[44]  J. Smith,et al.  Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects , 1995, The Journal of cell biology.

[45]  K. Miyazono,et al.  Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. , 1995, Endocrinology.

[46]  J. Massagué,et al.  Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells , 1994, Molecular and Cellular Biology.

[47]  D. Riddle,et al.  Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. , 1994, The Journal of biological chemistry.

[48]  J. Massagué,et al.  Betaglycan presents ligand to the TGFβ signaling receptor , 1993, Cell.

[49]  R. Weinberg,et al.  Expression cloning and characterization of the TGF-β type III receptor , 1991, Cell.

[50]  J. Massagué,et al.  Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system , 1991, Cell.